News

OUHSC Research News – Monday, June 6, 2022

Published: Monday, June 6, 2022

OUHSC Research News – Monday, June 6, 2022

SoonerTrack II Update

After careful consideration and in response to resource constraints during the week of July 4^th, the Office of Research Administration (ORA) has decided to postpone the SoonerTrack II go-live date to 7/11/22. This change is being made to ensure that adequate support staff from various departments (e.g. PeopleSoft Financials, IT Security, ORA, etc.) is available to assist the Principal Investigators and departmental staff with use of the system during the first week of go-live.

ORA continues work on development and configuration of SoonerTrack II. User Acceptance Testing (UAT) of SoonerTrack II with departmental testers began on 5/31/22 and will continue through 6/17/22. ORA appreciates their time and effort in assisting us with the testing of the system.

Stay tuned for SoonerTrack II training and live demonstration announcements. In the meantime, please check your current SoonerTrack tickets for any outstanding statuses that need to be completed/withdrawn prior to the go-live date. If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.

Updated RPPR Instruction Guide Available

An updated RPPR Instruction Guide is now available. The instruction guide reflects changes associated with recently issued guide notices on Other Support and Biosketch format pages, human subjects, Trainee Diversity Report and NRSA childcare costs reporting (see NOT-OD-22-130 for details). Note that a final RPPR Instruction Guide will be published on June 23 to reflect the revised screenshots accompanying the new look and feel of the RPPR module.

NIH Disclosures Guidance

As a reminder, NIH policy now requires applicants and awardees to disclose “all resources made available to a researcher in support of and/or related to all of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant.” Further details on what needs to be disclosed can be found on Notice NOT-OD-19-114.

If you are not sure whether a particular activity should be reported in the biosketch, other support, or annual project reports, check out NIH Disclosures Table. This table provides a list of various activities and when they need to be disclosed.

ORA Notice: CRIOC (Clinical Research Informatics Oversight Committee) Approval

ORA has stablished a process for actively managing requests to share health data with third parties. Regardless of whether or not human subjects are involved in research project, Principal Investigators (PIs) are required to answer the following questions. We are asking these questions manually until SoonerTrack II is up and running with the questions as part of the request form.

Please note that if OU Health patient data is being used, we cannot proceed with posting the Notice of Award (NOA) until the CRIOC approval is received.

Are you sharing any data that contains Protected Health Information (PHI), Personally Identifiable Information (PII), Limited Data Set (LDS), De-Identified, or Other?
- If no, no further information necessary.
- If yes, answer the following:

What type of data (please state PHI, PII, LDS, De-Identified, or Other; may be a combination)?
Does the data being shared come from OU Health patient data?
With respect to the data being shared, is OUHSC the Provider, Recipient, or Mutual?
Finally, please provide a description of the data being shared

Workshops and Seminars

Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 19th Annual Harold Hamm Diabetes Center Research Symposium. This in-person event will be held on Friday, November 11, 2022 at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be announced in the coming weeks. Additional details will be posted on be posted here. Questions? Please email: Katie-Hoefling@ouhsc.edu

OUHSC Funding Opportunities

Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).

Eurofarma, a Brazilian pharmaceutical company, is seeking validated targets, novel compounds, and/or adjuvant compounds for antibacterial drugs/therapies. Highest priority given to small molecule bactericidal drugs with validated targets; gram-negative and ESKAPE pathogens are of particular interest. Out of scope: compositions targeting mycobacteria. Submission entails a 1-pg non-confidential summary of technology. (deadline 06/06)
Grunenthal, a global leader in pain management, is seeking new chemical entities and novel targets (linked to nociceptive pathways) for treatment of pain in humans. In scope: compounds (modality agnostic) to provide pain relief in osteoarthritic pain, peripheral neuropathic pain, chronic low back pain and prevention of post-surgical chronic pain. Out of Scope: targets related to opioids, local anesthetics or cannabinoid pathways of the NGF-pathway; cell therapies, re-purposed and re-formulated existing drugs. Submission entails a 1-pg non-confidential summary of technology. (deadline 06/12)
A plant breeding an biotechnology company (anonymous) is seeking solutions to allow indoor cultivation and crossing of soybeans within a 60-day lifecycle. Of particular interest is growth regulators in combination with indoor breeding protocols to overcome flowering delay and speed lifecycle in tropical or subtropical varieties. Submission entails a 1-pg non-confidential summary of technology. (deadline 06/12)

NIH Notices

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.

NIH Funding Opportunities

PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
(PA-22-176)
Application Receipt Date(s): Standard dates apply
PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
(PA-22-177)
Application Receipt Date(s): Standard dates apply
PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
(PA-22-178)
Application Receipt Date(s): Standard dates apply
PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
(PA-22-179)
Application Receipt Date(s): Standard dates apply
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
(PAR-22-194)
Application Receipt Date(s): October 17, 2024
Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trial Not Allowed)
(RFA-DA-23-015)
Application Receipt Date(s): November 14, 2022
Cooperative Agreement to Support an Evidence-Based Clinical Practice Guideline for the Safe Tapering of Benzodiazepines (U01) Clinical Trials Not Allowed
(RFA-FD-22-027)
Application Receipt Date(s): August 03, 2022
Cooperative Agreement to Support an Evidence-Based Clinical Practice Guideline for the Management of Postoperative Pain After Surgeries in Obstetric Patients (U01) Clinical Trials Not Allowed
(RFA-FD-22-028)
Application Receipt Date(s): August 03, 2022

Other Funding Opportunities

The Cystic Fibrosis Foundation (CFF): Biological Basis for CF-Related Diabetes Program

Description: The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease.

Application deadline: August 2, 2022

Link to Full Announcement: https://www.cff.org/researchers/biological-basis-cf-related-diabetes-program

The Cystic Fibrosis Foundation (CFF): Path to a Cure -- Collaborative Research Grant

Description: Path to a Cure: Collaborative Research Grants are intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat CF, with an emphasis on advancing CFTR gene repair and replacement approaches. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Proposals must include preliminary data to justify support from the Cystic Fibrosis Foundation.

Application deadline: July 14, 2022

Link to Full Announcement: https://www.cff.org/researchers/path-cure-collaborative-research-grant

2022 Michelson Prizes: Next Generation Grants

Description: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Michelson Prizes are awarding research that is highly innovative and impactful, with the potential to be applied across many diseases.

Application deadline: June 26, 2022

Link to Full Announcement: https://www.humanvaccinesproject.org/michelson-prizes/

The Vilcek Foundation 2023 Vilcek Prizes for Creative Promise in Biomedical Science

Description: The Vilcek Foundation will award three Creative Promise Prizes of $50,000 each to young, immigrant biomedical scientists who demonstrate outstanding early achievement. Applicants should have been born outside of the United States and be 38 years of age or younger, but limited exceptions to the age requirement will be granted to those who have taken time off for caregiving, medical, military, or parental leave. Three winners will each receive a $50,000 unrestricted cash prize and be honored at an awards ceremony in New York City in April 2023.

Deadline: June 10, 2022

Link to Full Announcement: https://vilcek.org/prizes/vilcek-prizes-for-creative-promise/creative-promise-prizes-biomedical-science/

DoD FY22 Chronic Pain Management Research Program (CPMRP)